Status:
UNKNOWN
Long-term Outcomes for Acute Myeloid Leukemia Patients
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Collaborating Sponsors:
European Organisation for Research and Treatment of Cancer - EORTC
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This international observational study aims at examining the patterns of health-related quality of life differences between long-term acute myeloid leukemia patients and their healthy peers from the g...
Eligibility Criteria
Inclusion
- Diagnosis of all subtypes of de novo AML, according to WHO criteria (at least 20% blasts in the bone marrow), except acute promyelocytic leukemia (APL).
- Age at AML diagnosis ≥ 18 years,
- Date of AML diagnosis at least 5 years before study enrollment,
- AML-free status at study enrollment,
- Written informed consent provided.
Exclusion
- Major cognitive deficit or psychiatric problems hampering a self-reported evaluation,
- Not speaking and reading the language of the participating country,
- More than 75 years at the time of study enrollment,
- Receiving any active treatment for AML at the time of study enrollment.
Key Trial Info
Start Date :
May 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
343 Patients enrolled
Trial Details
Trial ID
NCT03755856
Start Date
May 16 2019
End Date
December 1 2022
Last Update
March 4 2020
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Gasthuisberg
Leuven, Belgium
2
CHR Citadelle-CHU
Liège, Belgium
3
University of Liège
Liège, Belgium
4
KBC Rijeka
Rijeka, Croatia